Shanghai Haohai Biological Technology Co., Ltd. (HKG:6826)

Revenue by Segment

Financials in millions CNY. Fiscal year is January - December.

Fiscal Year	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020	FY 2019	FY 2018	FY 2017	FY 2016
Period Ending	Dec 31, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021	Dec 31, 2020	Dec 31, 2019	Dec 31, 2018	Dec 31, 2017	Dec 31, 2016
Production and Sale of Biologics, Medical Hyaluronic Acid	2.45B	2.68B	2.63B	2.10B	1.75B
Total	2.45B	2.68B	2.63B	2.10B	1.75B

Revenue by Geography

Financials in millions CNY. Fiscal year is January - December.

Fiscal Year	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020	FY 2019	FY 2018	FY 2017	FY 2016
Period Ending	Dec 31, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021	Dec 31, 2020	Dec 31, 2019	Dec 31, 2018	Dec 31, 2017	Dec 31, 2016
Mainland China	2.04B	2.25B	2.18B	1.70B	1.54B
Europe	155.10M	154.22M	136.05M	140.81M	66.97M
United States of America (USA)	112.46M	137.78M	120.28M	103.72M	82.92M
Other Regions and Countries	141.96M	141.79M	196.77M	159.83M	57.64M
Total	2.45B	2.68B	2.63B	2.10B	1.75B

Data Source: S&P Global Market Intelligence Last updated: Mar 31, 2026

Financial data is provided by S&P Global Market Intelligence and updates within hours after each earnings release, which is every three months for this company.

Update frequency:

Quarterly

Last checked:

Jul 26, 2026

Data Sources Report a data error